Halozyme Therapeutics, Inc. capital & dividend

Leverage, liquidity, debt coverage and shareholder-distribution metrics.

Leverage

Debt / equity: 9.76x
Net debt / equity: 8.35x
Debt / assets: 0.80x
Debt / EBITDA: 3.44x
Net debt / EBITDA: 2.94x

Liquidity & coverage

Current ratio: 2.76x
Quick ratio: 2.33x
Cash ratio: 0.88x
Interest coverage: 44.97x
EBITDA / interest: 32.65x
Working capital: $639.8M

Cash & dividend

FCF / debt: 0.31x
Cash flow / debt: 0.32x
Dividend per share: —
Dividend yield: —
Dividend growth 1y: —

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.